189 related articles for article (PubMed ID: 16797237)
1. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
Watanabe T; Masuyama J; Sohma Y; Inazawa H; Horie K; Kojima K; Uemura Y; Aoki Y; Kaga S; Minota S; Tanaka T; Yamaguchi Y; Kobayashi T; Serizawa I
Clin Immunol; 2006 Sep; 120(3):247-59. PubMed ID: 16797237
[TBL] [Abstract][Full Text] [Related]
2. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
3. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
Shah A; Lowenstein H; Chant A; Khan A
Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
[TBL] [Abstract][Full Text] [Related]
4. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.
Rowan WC; Hale G; Tite JP; Brett SJ
Int Immunol; 1995 Jan; 7(1):69-77. PubMed ID: 7718516
[TBL] [Abstract][Full Text] [Related]
5. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.
Singh AK; Seavey CN; Horvath KA; Mohiuddin MM
Xenotransplantation; 2012; 19(2):102-11. PubMed ID: 22497512
[TBL] [Abstract][Full Text] [Related]
6. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
[TBL] [Abstract][Full Text] [Related]
7. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells.
Sugita S; Keino H; Futagami Y; Takase H; Mochizuki M; Stein-Streilein J; Streilein JW
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5376-84. PubMed ID: 17122127
[TBL] [Abstract][Full Text] [Related]
8. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression.
Zhang P; Gao F; Wang Q; Wang X; Zhu F; Ma C; Sun W; Zhang L
Scand J Immunol; 2007 Oct; 66(4):435-40. PubMed ID: 17850588
[TBL] [Abstract][Full Text] [Related]
9. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
10. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
11. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
12. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
[TBL] [Abstract][Full Text] [Related]
13. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
[TBL] [Abstract][Full Text] [Related]
14. IL-2-independent generation of FOXP3(+)CD4(+)CD8(+)CD25(+) cytotoxic regulatory T cell lines from human umbilical cord blood.
Nakamura S; Suzuki M; Sugimoto A; Tsuji-Takayama K; Yamamoto M; Otani T; Inoue T; Harashima A; Okochi A; Motoda R; Yamasaki F; Orita K; Kibata M
Exp Hematol; 2007 Feb; 35(2):287-96. PubMed ID: 17258077
[TBL] [Abstract][Full Text] [Related]
15. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
[TBL] [Abstract][Full Text] [Related]
16. Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals.
Sugita S; Horie S; Yamada Y; Keino H; Usui Y; Takeuchi M; Mochizuki M
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2529-36. PubMed ID: 19959639
[TBL] [Abstract][Full Text] [Related]
17. A kinetic comparative study on lymphocyte responses to superantigen and phytohemagglutinin: reciprocal presentation of superantigen on the surface of activated lymphocytes.
Ijichi S; Yamano Y; Osame M; Hall WW
Cell Immunol; 1996 Nov; 173(2):312-6. PubMed ID: 8912892
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).
Cao T; Soto A; Zhou W; Wang W; Eck S; Walker M; Harriman G; Li L
Cell Immunol; 2009; 258(1):65-71. PubMed ID: 19410243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]